Sign In
Buy SNSE
$15.85
-0.250 (-1.55%)
At Close: Jun 03, 2026
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Friday, 15'th May 2026
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. â
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:30am, Friday, 15'th May 2026
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
07:30am, Tuesday, 05'th May 2026
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Pha
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
07:30am, Thursday, 09'th Apr 2026
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
07:30am, Monday, 30'th Mar 2026
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth
Sensei Biotherapeutics (SNSE) Expected to Announce Quarterly Earnings on Friday
01:04am, Friday, 20'th Mar 2026
Sensei Biotherapeutics (NASDAQ: SNSE - Get Free Report) is expected to be announcing its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
11:00am, Thursday, 19'th Mar 2026
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary - Big money is moving back into biotech. Institutional investors have been writing some of the large
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00am, Tuesday, 17'th Mar 2026
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Sensei's Board of Directors granted a new employee an option to purchase 166,435
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Up 1,973.5% in February
04:21am, Wednesday, 11'th Mar 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 5
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00am, Wednesday, 25'th Feb 2026
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Sensei's Board of Directors granted 17 new employees, in the aggregate, optio
Sensei Biotherapeutics Stock Soars 230% After Faeth Deal
12:09pm, Wednesday, 18'th Feb 2026
SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pipeline targeting cancer.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
08:00am, Wednesday, 18'th Feb 2026
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi
Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis
02:16am, Wednesday, 14'th Jan 2026
Cynata Therapeutics (OTCMKTS:CYYNF - Get Free Report) and Sensei Biotherapeutics (NASDAQ: SNSE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will comp
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
08:00am, Wednesday, 07'th Jan 2026
PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immun
What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump?
01:31am, Friday, 05'th Dec 2025
Sensei Biotherapeutics surged in after-hours trading Thursday, with strong recent gains and ongoing shareholder activity drawing attention.
